All In Biotech

Drug Trial Radar · NCT05059600

A Study To Assess The Safe-Use Conditions For Administration of ZULRESSO® in a Home Setting

Assessment of Safe-use Conditions for Administration of ZULRESSO in a Home Setting

Last checked: Nov 20, 2026Latest source record: Sep 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

52

Actual

Start

Oct 8, 2021

Primary completion

Jul 14, 2022

Study completion Jul 14, 2022

Sponsor

Lead sponsor
Supernus Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Sep 28, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study was to evaluate whether the safe-use conditions for administration of brexanolone (ZULRESSO®) can be implemented in a home setting.

Conditions

  • Postpartum Depression

Interventions

  • ZULRESSO®Drug

    Intravenous infusion of ZULRESSO®.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With At Least One Treatment-Emergent Adverse Event (TEAE) Leading to Dose Interruption/DiscontinuationTime frame: Up to Day 3

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Sage Investigational Site

    Culver City, California

  • Virtual Site (recruiting nationwide)

    Culver City, California

  • Sage Investigational Site

    Miramar, Florida

  • Sage Investigational Site

    Pompano Beach, Florida

  • Sage Investigational Site

    New York, New York

  • Sage Investigational Site

    League City, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.